Testicular Cancer

Testicular cancer is one of the most common neoplastic conditions affecting intact male dogs, accounting for a significant proportion of all tumors diagnosed in unneutered males. The condition involves the uncontrolled growth of abnormal cells within one or both testicles, arising from the various specialized cell types that compose the testicular tissue. Because the testicle contains several distinct cell populations, each with unique functions, testicular cancer in dogs encompasses several different tumor types with varying biological behaviors.

The three primary types of testicular tumors in dogs are Sertoli cell tumors, seminomas, and interstitial (Leydig) cell tumors. These three tumor types occur with roughly equal frequency in the general canine population, though their relative proportions vary depending on factors such as breed, age, and whether the affected testicle is normally descended or cryptorchid. Each tumor type arises from a different cell lineage within the testicle and carries distinct clinical implications regarding hormone production, metastatic potential, and associated paraneoplastic syndromes.

Testicular tumors are predominantly a disease of older intact male dogs, with the average age at diagnosis typically falling between 10 and 11 years. However, younger dogs can also be affected, particularly those with cryptorchid testicles, which are at substantially increased risk for tumor development. The incidence of testicular cancer has decreased in many pet populations due to the widespread practice of elective neutering, but it remains an important clinical consideration in intact males and in regions or cultures where neutering is less common.

The clinical significance of testicular cancer extends beyond the local tumor itself. Certain tumor types, particularly Sertoli cell tumors, can produce excessive amounts of estrogen and other hormones that cause systemic effects throughout the body. These paraneoplastic syndromes can produce dramatic changes in the dog's appearance and health, including feminization, bone marrow suppression, and skin changes, sometimes bringing the dog to veterinary attention before the testicular mass itself is noticed.

Sertoli cell tumors arise from the Sertoli cells, which normally function to support and nourish developing sperm cells within the seminiferous tubules. These tumors are of particular clinical significance because of their propensity to produce estrogen, which can lead to a constellation of feminizing effects known as hyperestrogenism. Sertoli cell tumors are the most common type found in cryptorchid testicles and carry a metastatic rate of approximately 10 to 15 percent, making them the most clinically aggressive of the three common testicular tumor types.

Seminomas originate from the germ cells that would normally differentiate into spermatozoa. These tumors tend to grow as soft, homogeneous masses within the testicular parenchyma and may become quite large before detection. Seminomas are generally considered to have low malignant potential, with metastatic rates typically reported below 10 percent. While seminomas can occasionally produce hormones, they are less frequently associated with paraneoplastic endocrine syndromes than Sertoli cell tumors. They occur in both normally descended and cryptorchid testicles.

Interstitial cell tumors, also called Leydig cell tumors, develop from the testosterone-producing interstitial cells located between the seminiferous tubules. These are generally the most benign of the three tumor types and are frequently discovered incidentally during necropsy or during castration performed for other reasons. Interstitial cell tumors are typically small, well-circumscribed nodules that rarely cause clinical signs and have an extremely low metastatic rate. They occur almost exclusively in normally descended, scrotal testicles.

It is not uncommon for dogs to develop more than one type of testicular tumor simultaneously, either within the same testicle or in opposite testicles. Mixed tumors containing elements of two or more tumor types within a single mass also occur. The presence of multiple tumor types can complicate the clinical picture, particularly when one component is hormone-producing while another is not, and reinforces the importance of thorough histopathological examination of all excised testicular tissue.

Rare testicular tumor types that occasionally occur in dogs include embryonal carcinomas, teratomas, gonadoblastomas, and lymphomas. These uncommon neoplasms may behave more aggressively than the three common tumor types and may require additional staging and treatment beyond standard castration. Their diagnosis relies on histopathological examination, as they cannot be reliably distinguished from the common tumor types based on gross appearance alone.

The single most significant risk factor for testicular cancer in dogs is cryptorchidism, a condition in which one or both testicles fail to descend into the scrotum during normal development. Cryptorchid testicles, whether retained in the abdomen or in the inguinal canal, are exposed to higher temperatures than normally descended testicles and undergo degenerative changes that predispose them to neoplastic transformation. The risk of tumor development in a cryptorchid testicle is estimated to be approximately 10 to 14 times higher than in a normally descended testicle.

Abdominally retained testicles carry a higher risk than inguinally retained ones, likely due to the greater temperature differential and the more complete isolation from the temperature-regulating mechanisms of the scrotum. Sertoli cell tumors and seminomas are the predominant tumor types in cryptorchid testicles, while interstitial cell tumors are rare in undescended gonads. The increased risk associated with cryptorchidism underscores the veterinary recommendation for early castration of cryptorchid dogs, even when the retained testicle is not palpable and requires abdominal exploration for removal.

Advancing age is another well-established risk factor for testicular tumor development. The incidence of testicular neoplasia increases progressively with age in intact male dogs, with peak incidence occurring between 10 and 12 years of age. The cumulative exposure of testicular cells to hormonal stimulation, oxidative stress, and other age-related changes likely contributes to the increased tumor risk in older dogs. However, the age relationship is modified by cryptorchidism, with cryptorchid dogs often developing tumors at younger ages than dogs with normally descended testicles.

Breed predisposition has been documented for several breeds, suggesting a genetic component to testicular cancer susceptibility. Boxers, German Shepherds, Afghan Hounds, Weimaraners, Shetland Sheepdogs, and Collies have been reported to have higher incidence rates compared to mixed-breed dogs. The genetic factors underlying this breed predisposition are not fully characterized but may involve variations in tumor suppressor genes, DNA repair mechanisms, or hormonal regulation pathways.

Environmental factors have been investigated as potential contributors to testicular cancer risk in dogs, paralleling concerns about rising testicular cancer rates in human populations. Exposure to certain pesticides, industrial chemicals, and endocrine-disrupting compounds has been hypothesized to increase the risk of testicular neoplasia, though definitive evidence in the canine population remains limited. The dog's role as a sentinel species for environmental carcinogen exposure continues to be an area of active research interest.

The clinical presentation of testicular cancer in dogs varies considerably depending on the tumor type, location, size, and whether hormone production is involved. In many cases, particularly with interstitial cell tumors and early-stage seminomas, the dog may show no outward signs of disease, and the tumor is discovered only during routine physical examination or during castration performed for other reasons.

The most straightforward clinical sign is a palpable mass or asymmetric enlargement of one or both testicles. Owners or veterinarians may notice that one testicle appears or feels larger, firmer, or irregularly shaped compared to the other. In some cases, the affected testicle may be dramatically enlarged, while in others, the tumor may be small and detectable only on careful palpation. The contralateral testicle may appear atrophied or smaller than normal, particularly when the tumor-bearing testicle is producing excess estrogen.

Feminization syndrome, caused by excess estrogen production, is one of the most clinically striking presentations of testicular cancer and is most commonly associated with Sertoli cell tumors, though seminomas and rarely other tumor types can also produce estrogen. Signs of feminization include bilateral symmetrical hair loss, particularly along the flanks, perineum, and ventral abdomen; hyperpigmentation of the skin; gynecomastia or enlargement of the mammary glands; pendulous prepuce; decreased libido; and attraction of other male dogs. These changes develop gradually over weeks to months and may be the primary reason the dog is brought to veterinary attention.

Bone marrow suppression is a serious and potentially life-threatening complication of estrogen-producing testicular tumors. Chronic hyperestrogenism can cause aplastic anemia, in which the bone marrow fails to produce adequate numbers of red blood cells, white blood cells, and platelets. Dogs with estrogen-induced bone marrow suppression may present with lethargy, pale mucous membranes, weakness, increased susceptibility to infections, and spontaneous bleeding or bruising. This complication carries a grave prognosis if not recognized and addressed promptly.

In cases involving cryptorchid testicles, the tumor may develop within the abdomen, making direct palpation impossible. Abdominal testicular tumors may grow to considerable size before causing clinical signs, which can include abdominal distension, discomfort, difficulty urinating or defecating due to mass effect on adjacent organs, and the systemic effects of hormone production. Torsion of an enlarged abdominal testicle is an acute surgical emergency that can present with sudden severe abdominal pain, vomiting, and cardiovascular collapse.

The diagnostic workup for suspected testicular cancer typically begins with a thorough physical examination, including careful palpation of both testicles and the inguinal regions. The veterinarian will assess testicular size, symmetry, consistency, and the presence of any palpable masses or irregularities. In cryptorchid dogs, abdominal palpation may reveal a mass in the region where the retained testicle would be expected, though advanced imaging is usually required for definitive localization.

Ultrasonographic examination of the testicles is a valuable noninvasive diagnostic tool that can identify intratesticular masses, characterize their echogenicity and vascularity, and help differentiate neoplastic from non-neoplastic causes of testicular enlargement. Abdominal ultrasound is essential in cryptorchid dogs to locate retained testicles and evaluate them for neoplastic changes. Ultrasound can also assess regional lymph nodes and abdominal organs for evidence of metastatic disease.

Hormonal assays can support the diagnosis, particularly when a hormone-producing tumor is suspected. Serum estradiol levels may be elevated in dogs with estrogen-producing Sertoli cell tumors or seminomas, and this finding, combined with clinical signs of feminization, strongly suggests a functional testicular neoplasm. Testosterone levels may be variably affected depending on the tumor type and the degree to which normal testicular tissue has been replaced or suppressed.

Complete blood count and serum chemistry panel are important components of the diagnostic workup. The CBC may reveal anemia, thrombocytopenia, or leukopenia in dogs with estrogen-induced bone marrow suppression, or may show a regenerative anemia if bleeding has occurred. Serum chemistry helps assess overall organ function and identify any metabolic derangements that could affect anesthetic safety for surgical intervention.

Staging to assess for metastatic disease is recommended, particularly for Sertoli cell tumors and seminomas, which have higher metastatic potential than interstitial cell tumors. Staging typically includes thoracic radiographs to evaluate the lungs for pulmonary metastases, abdominal ultrasound to assess sublumbar lymph nodes and abdominal organs, and in some cases, CT scanning for more comprehensive evaluation. Fine-needle aspirate of enlarged lymph nodes can confirm or rule out metastatic involvement. Definitive diagnosis of tumor type requires histopathological examination of the excised testicle following castration.

Bilateral castration (orchiectomy) is the standard treatment for testicular cancer in dogs and is curative in the vast majority of cases. The surgery involves removal of both testicles, regardless of whether one or both are affected, as the contralateral testicle may harbor microscopic tumor foci and the dog's reproductive function is no longer a priority once cancer has been diagnosed. Castration eliminates the source of both the tumor and any hormone production responsible for paraneoplastic syndromes.

The surgical approach depends on the location of the affected testicle. For normally descended, scrotal testicles, standard prescrotal or scrotal orchiectomy is performed using routine surgical techniques. The procedure is well-tolerated, carries minimal anesthetic risk in otherwise healthy dogs, and typically requires only brief hospitalization. Recovery is rapid, with most dogs returning to normal activity within one to two weeks.

Cryptorchid testicles require a modified surgical approach. Inguinally retained testicles may be accessible through an inguinal incision, while abdominally retained testicles necessitate a celiotomy or laparoscopic approach for identification and removal. Abdominal exploration should be thorough, as cryptorchid testicular tumors can become quite large and may have developed adhesions to surrounding structures. Laparoscopic techniques offer the advantages of smaller incisions, reduced postoperative pain, and faster recovery compared to traditional open celiotomy.

In dogs presenting with estrogen-induced bone marrow suppression, the clinical situation requires urgent attention. Castration should be performed as soon as the patient can be safely anesthetized, as removal of the estrogen source is essential for bone marrow recovery. However, these patients are high-risk surgical candidates due to anemia, thrombocytopenia, and immunosuppression, and may require supportive care including blood transfusions, platelet-rich plasma, and broad-spectrum antibiotics before, during, and after surgery. Bone marrow recovery following castration can take weeks to months, and some severely affected dogs may not recover adequate marrow function.

For the uncommon cases in which metastatic disease is identified at the time of diagnosis, chemotherapy may be considered as an adjunctive treatment following castration. Cisplatin-based protocols have shown some efficacy against metastatic testicular tumors in dogs, drawing on the well-established success of platinum-based chemotherapy for human testicular cancer. However, the evidence base for chemotherapy in canine testicular cancer is limited, and treatment decisions should be made in consultation with a veterinary oncologist. Radiation therapy may be considered for localized metastatic lesions that are not amenable to surgical excision.

The overall prognosis for testicular cancer in dogs is excellent when the condition is diagnosed and treated with castration before metastasis has occurred. The vast majority of testicular tumors are benign or low-grade malignancies that are completely cured by surgical removal. Interstitial cell tumors carry the best prognosis, with metastasis being exceedingly rare, followed by seminomas and Sertoli cell tumors.

For dogs with non-metastatic testicular tumors treated with castration, the cure rate approaches 90 to 95 percent. Following surgery, feminization signs associated with hormone-producing tumors typically resolve over a period of weeks to months as estrogen levels normalize and the body's tissues recover from the effects of chronic hyperestrogenism. Hair regrowth in alopecic areas may take several months and may initially appear different in color or texture before returning to normal.

The prognosis becomes more guarded in cases complicated by estrogen-induced bone marrow suppression. While removal of the estrogen source through castration allows the potential for bone marrow recovery, the regenerative capacity of the marrow depends on the severity and duration of suppression. Dogs with mild to moderate marrow suppression generally recover well, though recovery may require four to eight weeks of supportive care. Severe aplastic anemia carries a mortality rate that can exceed 50 percent, even with aggressive supportive treatment.

Metastatic testicular cancer, while uncommon, carries a significantly worse prognosis. Metastatic Sertoli cell tumors and seminomas may respond to chemotherapy, but long-term outcomes for dogs with widespread metastatic disease are generally poor. Regional lymph node metastasis may be managed with surgical excision and adjuvant therapy, while distant metastatic disease to the lungs or other organs typically indicates advanced disease with limited treatment options.

Long-term follow-up after castration for testicular cancer should include periodic physical examinations and, in cases of malignant tumors, surveillance imaging to monitor for recurrence or late metastasis. Most recurrences, when they occur, develop within the first year following surgery, making regular veterinary check-ups during this period particularly important.

The most effective strategy for preventing testicular cancer in dogs is elective castration, ideally performed before the dog reaches sexual maturity or at the time recommended by the attending veterinarian based on breed-specific growth considerations. Neutering eliminates the possibility of testicular neoplasia entirely by removing the target organ, and it is the primary reason that testicular cancer is relatively uncommon in the overall pet dog population despite being one of the most frequent tumors in intact males.

Early identification and surgical correction of cryptorchidism is critically important for cancer prevention. Because cryptorchid testicles carry a dramatically increased risk of neoplastic transformation, veterinary guidelines uniformly recommend castration for all cryptorchid dogs, regardless of whether the owner intends to breed the animal. Since cryptorchidism itself is a heritable condition, affected dogs should not be bred even if the retained testicle could theoretically be brought into the scrotum through orchiopexy, as this would perpetuate the genetic defect in offspring.

For owners who choose to maintain their dogs intact for breeding purposes, performance activities, or personal preference, regular veterinary examinations with specific attention to testicular palpation are essential for early detection. Monthly self-examination of the testicles by the owner, similar to the practice recommended for human males, can help identify changes in size, shape, or consistency between veterinary visits. Any asymmetry, firmness, or palpable nodularity should prompt veterinary evaluation.

Breeding dogs should receive regular reproductive health assessments that include testicular examination and, in some cases, periodic ultrasonographic evaluation, particularly as they age. Breeders should maintain records of testicular health findings and be prepared to retire dogs from breeding programs and consider castration if abnormalities are detected. The decision to continue breeding an older intact male should be balanced against the increasing risk of testicular neoplasia with advancing age.

Genetic considerations in breeding programs should include awareness of the familial nature of cryptorchidism and possibly of testicular cancer susceptibility. While routine genetic testing for testicular cancer risk is not currently available in dogs, breeders should track the incidence of both cryptorchidism and testicular tumors within their breeding lines and make informed decisions about which dogs to include in or exclude from their programs based on health history data.

Paraneoplastic syndromes associated with testicular cancer represent some of the most clinically significant aspects of the disease and can produce systemic effects that are more immediately threatening than the primary tumor itself. These syndromes result from the production of hormones, cytokines, or other biologically active substances by the tumor cells and can affect multiple organ systems throughout the body.

Hyperestrogenism is the most well-recognized paraneoplastic syndrome associated with testicular tumors, occurring most frequently with Sertoli cell tumors but occasionally with seminomas and rarely with interstitial cell tumors. The excess estrogen produced by the tumor acts on target tissues throughout the body, producing the characteristic feminization syndrome. Dermatological manifestations include bilateral symmetrical alopecia that typically begins in the perineal region and extends to the flanks, ventral abdomen, and chest; hyperpigmentation of affected skin areas; and thinning of the skin with decreased elasticity.

The effects of chronic hyperestrogenism on the bone marrow represent the most dangerous paraneoplastic complication. Estrogen at supraphysiological concentrations is directly toxic to hematopoietic stem cells in the bone marrow, leading to progressive suppression of all three cell lines: red blood cells, white blood cells, and platelets. This condition, known as estrogen-induced pancytopenia or aplastic anemia, can develop insidiously over weeks to months before becoming clinically apparent. By the time symptoms of marrow failure manifest, the suppression may be severe and potentially irreversible.

Prostate changes are another important paraneoplastic effect of estrogen-producing testicular tumors. While testosterone normally drives prostatic growth and hyperplasia, the altered hormonal milieu created by excess estrogen can lead to squamous metaplasia of the prostatic epithelium. This transformation predisposes the prostate to cystic changes, infection, and abscessation, which may present as urinary difficulties, straining to defecate, or purulent urethral discharge. These prostatic complications may require specific treatment in addition to addressing the primary testicular tumor.

Less common paraneoplastic effects include behavioral changes such as decreased aggression and libido, attraction of other male dogs due to altered pheromone production, and rarely, galactorrhea or milk production from the mammary glands. In dogs with interstitial cell tumors that produce excess testosterone or its metabolites, the opposite pattern of masculinization or exaggerated male characteristics may occasionally be observed, including increased territorial behavior, prostatic hyperplasia, and perianal gland adenomas.

Testicular cancer in dogs and humans shares several fundamental characteristics, making the canine disease a valuable comparative model for human oncology research. Both species develop germ cell tumors and sex cord-stromal tumors within the testes, and cryptorchidism represents a significant risk factor in both species. However, important differences exist in the relative frequencies of tumor types, age of onset, biological behavior, and treatment approaches.

In humans, germ cell tumors, particularly seminomas and nonseminomatous germ cell tumors, account for approximately 95 percent of testicular cancers, with sex cord-stromal tumors being rare. In dogs, the distribution is much more even, with Sertoli cell tumors, seminomas, and interstitial cell tumors each comprising roughly one-third of cases. This difference in tumor type distribution has implications for comparative research, as the biological behavior and molecular characteristics of each tumor type differ between species.

The age of peak incidence differs markedly between species. Human testicular cancer predominantly affects young men between 15 and 44 years of age, making it one of the few cancers that is most common in young adults. In contrast, canine testicular cancer is primarily a disease of older dogs, with peak incidence between 10 and 12 years of age. This difference may reflect distinct pathogenic mechanisms or different roles of developmental versus age-related factors in tumor initiation between the two species.

Treatment approaches show both similarities and differences. Orchiectomy is the primary surgical treatment in both species, and the prognosis for localized disease is excellent in both dogs and humans. However, the management of metastatic disease differs substantially. Human testicular cancer has become one of the most curable malignancies thanks to highly effective cisplatin-based chemotherapy regimens, with cure rates exceeding 95 percent even for advanced disease. The evidence base for chemotherapy in canine testicular cancer is much less developed, and metastatic disease in dogs generally carries a less favorable prognosis.

The canine model offers unique advantages for studying environmental risk factors for testicular cancer. Dogs share the same living environments as their human owners and are exposed to many of the same environmental chemicals and pollutants. The rising incidence of testicular cancer in human populations has been hypothesized to relate to environmental endocrine disruptors, and studying testicular cancer trends in dog populations can provide complementary epidemiological data. Several research groups have investigated whether geographic and temporal trends in canine testicular cancer mirror those seen in human populations, with the goal of identifying shared environmental risk factors.